Certainly not all of them. I'm expecting the FDA's awarding of BTD for NASH compounds to parallel the way the FDA handled HCV, where drug combinations rather than individual drugs were the recipients of most the BTD awards.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”